Oral Targeted Drug Delivery Systems: Gastric Retention Devices

Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice

Volumn , Issue , 2010, Pages 185-203

  Omidian, Hossein ^a   Park, Kinam ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Drug delivery system in stomach for drugs; Drug delivery, entrapment and release drug delivery system maintenance in stomach; Oral targeted drug delivery systems gastric retention devices

Indexed keywords

EID: 84885550110     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640487.ch12     Document Type: Chapter

References (149)

1. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr. Opin. Pharmacol. 2006;6(5):501-508.
2. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 1998;15(3): 243-284.
3. Hou SYE, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit. Rev. Ther. Drug Carrier Syst. 2003;20 (6):461-497.
4. Davis SS. Formulation strategies for absorption windows. Drug Discov. Today 2005;10(4):249-257.
5. Conway BR. Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr. Pharm. Des. 2005;11 (6):775-790.
6. Bardonnet PL, et al. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J. Control. Release 2006;111(1-2):1-18.
7. Atherton JC, et al. Scintigraphic assessment of the intragastric distribution and gastric-emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor. Aliment. Pharmacol. Ther. 1994;8(5):489-494.
8. Waterman KC.Acritical reviewof gastric retentive controlled drug delivery. Pharm. Dev. Technol. 2007;12(1):1-10.
9. Talukder R, Fassihi R. Gastroretentive delivery systems: a mini review. Drug Dev. Ind. Pharm. 2004;30(10):1019-1028.
10. Kiss D, Zelko R. Gastroretentive dosage forms. Acta Pharm. Hung. 2005;75(3):169-176.
11. Davis SS,Wilding EA,Wilding IR. Gastrointestinal transit of a matrix tablet formulation: comparison of canine and human data. Int. J. Pharm. 1993;94(1-3):235-238.
12. Karali TT. Gastrointestinal absorption of drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989;6:39.
13. Washinton N, Washington C, Wilson CG. Physiological Pharmaceutics: Barriers to Drug Absorption, 2nd edition, Taylor & Francis, New York, 2001, p 312.
14. Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv. 2003;10(3):151-160.
15. Umamaheswari RB, et al. Floating-bioadhesive microspheres containing acetohydroxamic acid for clearance of Helicobacter pylori. Drug Deliv. 2002;9(4):223-231.
16. Fukuda M, Peppas NA, McGinity JW. Floating hot-melt extruded tablets for gastroretentive controlled drug release system. J. Control. Release 2006;115(2):121-129.
17. Groning R, Berntgen M, Georgarakis M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur. J. Pharm. Biopharm. 1998;46(3):285-291.
18. Torrado S, et al. Chitosan-poly(acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention. Biomaterials 2004;25(5):917-923.
19. Rajinikanth PS, Balasubramaniam J, Mishra B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. Int. J. Pharm. 2007;335(1-2):114-122.
20. Dhumal RS, et al. Design and evaluation of bilayer floating tablets of cefuroxime axetil for bimodal release. J. Sci. Ind. Res. 2006;65(10):812-816.
21. Ali J, et al. Development and evaluation of a gastroretentive drug delivery system for the low-absorption-window drug celecoxib. PDA J. Pharm. Sci. Technol. 2007;61(2): 88-96.
22. Varshosaz J, Tavakoli N, Roozbahani F. Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets. Drug Deliv. 2006;13(4): 277-285.
23. Talwar N, Sen H, Staniforth JN. Orally administered controlled drug delivery system providing temporal and spatial control. US Patent 6,261,601, 2001, Ranbaxy Laboratories Limited (New Delhi, India).
24. Rajinikanth PS, Mishra B. Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H-pylori. J. Control. Release 2008;125:33-41.
25. Gambhire MN, et al. Development and in vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride. AAPS PharmSciTech 2007;8:E73.
26. Streubel A, Siepmann J, Bodmeier R. Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles. J. Microencapsul. 2003;20(3): 329-347.
27. JaiminiM,RanaAC,TanwarYS. Formulationandevaluationof famotidine floating tablets. Curr.DrugDeliv. 2007;4(1):51-55.
28. Sakkinen M, et al. Evaluation of microcrystalline chitosans for gastro-retentive drug delivery. Eur. J. Pharm. Sci. 2003;19 (5):345-353.
29. Gabapentin extended release-DepoMed: gabapentin ER, gabapentin gastric retention, gabapentin GR. Drugs R D 2007;8(5):317-320.
30. Sher P, et al. Low density porous carrier: drug adsorption and release study by response surface methodology using different solvents. Int. J. Pharm. 2007;331(1):72-83.
31. Tang YD, et al. Sustained release of hydrophobic and hydrophilic drugs from a floating dosage form. Int. J. Pharm. 2007;336(1):159-165.
32. Goole J, et al. New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer. Eur. J. Pharm. Biopharm. 2008;68:310-318.
33. Klausner EA, et al. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J. Control. Release 2003;88 (1):117-126.
34. Klausner EA, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm. Res. 2003;20(9):1466-1473.
35. Hoffman A, et al. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int. J. Pharm. 2004; 277(1-2):141-153.
36. Sharma S, Pawar A. Low density multiparticulate system for pulsatile release of meloxicam. Int. J. Pharm. 2006;313 (1-2):150-158.
37. Metformin extended release-DepoMed: metformin, metformin gastric retention, metformin GR. Drugs R D 2004;5(4): 231-233.
38. Metformin extended release: metformin gastric retention, metformin GR, metformin XR. Drugs R D 2005;6(5): 316-319.
39. Basak SC, Rahman J, Ramalingam M. Design and in vitro testing of a floatable gastroretentive tablet of metformin hydrochloride. Pharmazie 2007;62(2):145-148.
40. Cowles VE. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists. US Patent 6,451,808, 2002 (DepoMed, Inc., Menlo Park, CA).
41. Singh S, et al. Gastroretentive drug delivery system of metoclopramide hydrochloride: formulation and in vitro evaluation. Curr. Drug Deliv. 2007;4(4):269-275.
42. Chansanroj K, et al. Development of a multi-unit floating drug delivery system by hot melt coating technique with druglipid dispersion. J. Drug Deliv. Sci. Technol. 2007;17: 333-338.
43. Narendra C, Srinath MS, Babu G. Optimization of bilayer floating tablet containing metoprolol tartrate as a model drug for gastric retention. AAPS PharmSciTech 2006;7(2):E34.
44. Ishak RAH, et al. Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy. J. Control. Release 2007; 119(2):207-214.
45. Yang LB, Eshraghi J, Fassihi R. A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J. Control. Release 1999;57 (3):215-222.
46. Chavanpatil M, et al. Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Int. J. Pharm. 2005;304(1-2):178-184.
47. Chavanpatil MD, et al. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int. J. Pharm. 2006;316(1-2):86-92.
48. Ali J, Hasan S, Ali M. Formulation and development of gastroretentive drug delivery system for ofloxacin. Methods Find. Exp. Clin. Pharmacol. 2006;28(7):433-439.
49. Tougas G, et al. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. Aliment. Pharmacol. Ther. 2005;22(1):59-65.
50. Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS PharmSciTech 2004;5(2):
51. Hassan MA. Design and evaluation of a floating ranitidine tablet as a drug delivery system for oral application. J. Drug Deliv. Sci. Technol. 2007;17(2):125-128.
52. Rokhade AP, et al. Preparation and evaluation of cellulose acetate butyrate and poly(ethylene oxide) blend microspheres for gastroretentive floating delivery of repaglinide. J. Appl. Polym. Sci. 2007;105(5):2764-2771.
53. Stops F, et al. Citric acid prolongs the gastro-retention of a floating dosage form and increases bioavailability of riboflavin in the fasted state. Int. J. Pharm. 2006;308(1-2):14-24.
54. Kagan L, et al. Gastroretentive Accordion Pill: enhancement of riboflavin bioavailability in humans. J. Control. Release 2006;113(3):208-215.
55. Klausner EA, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res. 2002;19(10):1516-1523.
56. Ahmed IS, Ayres JW. Bioavailability of riboflavin from a gastric retention formulation. Int. J. Pharm. 2007;330(1-2): 146-154.
57. Goole J, et al. In vitro and in vivo evaluation in healthy human volunteers of floating riboflavin minitablets. J. Drug Deliv. Sci. Technol. 2006;16(5):351-356.
58. Hamdani J, et al. In vitro and in vivo evaluation of floating riboflavin pellets developed using the melt pelletization process. Int. J. Pharm. 2006;323(1-2):86-92.
59. Atyabi F, et al. Controlled drug release from coated floating ion exchange resin beads. J. Control. Release 1996;42(1): 25-28.
60. Elkheshen SA, et al. In vitro and in vivo evaluation of floating controlled release dosage forms of verapamil hydrochloride. Pharm. Ind. 2004;66(11):1364-1372.
61. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int. J. Pharm. 2002;241 (2):279-292.
62. Moes AJ. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 1993;10(2):143-195.
63. Jacques Timmermans AJM. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J. Pharm. Sci. 1994;83(1):18-24.
64. Reddy LHV, Murthy RSR. Floating dosage systems in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2002;19(6): 553-585.
65. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control. Release 2000;63(3):235-259.
66. Arora S, et al. Floating drug delivery systems: a review. AAPS PharmSciTech 2005;6(3):E372-E390.
67. Whitehead L, et al. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J. Control. Release 1998;55(1):3-12.
68. Dorozynski P, et al. The macromolecular polymers for the preparation of hydrodynamically balanced systems-methods of evaluation. Drug Dev. Ind. Pharm. 2004;30(9): 947-957.
69. Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates. Int. J. Pharm. 2000;210(1-2):45-49.
70. Desai S, Bolton S. A floating controlled-release drug-delivery system: in vitro-in vivo evaluation. Pharm. Res. 1993;10(9): 1321-1325.
71. Iannuccelli V, et al. Air compartment multiple-unit system for prolonged gastric residence. Part II. In vivo evaluation. Int. J. Pharm. 1998;174(1-2):55-62.
72. Atyabi F, et al. In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins. J. Control. Release 1996;42(2):105-113.
73. Bajpai SK, Tankhiwale R. Preparation, characterization and preliminary calcium release study of floating sodium alginate/ dextran-based hydrogel beads: part I. Polym. Int. 2008; 57:57-65.
74. Choi BY, et al. Preparation of alginate beads for floating drug delivery system: effects of CO2 gas-forming agents. Int. J. Pharm. 2002;239(1-2):81-91.
75. Sungthongjeen S, et al. Preparation and in vitro evaluation of a multiple-unit floating drug delivery system based on gas formation technique. Int. J. Pharm. 2006;324(2):136-143.
76. Soppimath KS, et al. Microspheres as floating drug-delivery systems to increase gastric retention of drugs. Drug Metab. Rev. 2001;33(2):149-160.
77. El-Gibaly I. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int. J. Pharm. 2002;249 (1-2):7-21.
78. Zou H, et al. Design and gamma-scintigraphic evaluation of a floating and pulsatile drug delivery system based on an impermeable cylinder. Chem. Pharm. Bull. 2007;55(4): 580-585.
79. Thairs S, et al. Effect of dose size, food and surface coating on the gastric residence and distribution of an ion exchange resin. Int. J. Pharm. 1998;176(1):47-53.
80. Jackson SJ, Bush D, Perkins AC. Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. Int. J. Pharm. 2001;212(1):55-62.
81. Leung SHS, Irons BK, Robinson JR. Polyanionic hydrogel as a gastric retentive system. J. Biomater. Sci. Polym. Ed. 1993;4 (5):483-492.
82. Groning R, Cloer C, Muller RS. Development and in vitro evaluation of expandable gastroretentive dosage forms based on compressed collagen sponges. Pharmazie 2006;61(7): 608-612.
83. Chen J, et al. Gastric retention properties of superporous hydrogel composites. J. Control. Release 2000;64(1-3): 39-51.
84. Omidian H, Park K. Experimental design for the synthesis of polyacrylamide superporous hydrogels. J. Bioact. Compat. Polym. 2002;17(6):433-450.
85. Qiu Y, Park K. Superporous IPN hydrogels having enhanced mechanical properties. AAPS PharmSciTech 2003;4(4): E51.
86. Omidian H, et al. Hydrogels having enhanced elasticity and mechanical strength properties. US Patent 6,960,617, 2005 (Purdue Research Foundation, West Lafayette, IN).
87. Omidian H, Rocca JG, Park K. Elastic, superporous hydrogel hybrids of polyacrylamide and sodium alginate. Macromol. Biosci. 2006;6(9):703-710.
88. Omidian H, Rocca JG. Formation of strong superporous hydrogels. US Patent 7,056,957, 2006 (Kos Pharmaceuticals, Inc., Miami, FL).
89. Gemeinhart RA, Park H, Park K. Effect of compression on fast swelling of poly(acrylamide-co-acrylic acid) superporous hydrogels. J. Biomed. Mater. Res. 55(1): 2001; 54-62.
90. Omidian H, Park K, Rocca JG. Recent developments in superporous hydrogels. J. Pharm. Pharmacol. 2007;59 (3):317-327.
91. Omidian H, Park K. Swelling agents and devices in oral drug delivery. J. Drug Deliv. Sci. Technol. 2008;18(2):82-93.
92. Omidian H, Rocca JG, Park K. Advances in superporous hydrogels. J. Control. Release 2005;102(1):3-12.
93. Park H, Park K, Kim D. Preparation and swelling behavior of chitosan-based superporous hydrogels for gastric retention application. J. Biomed. Mater. Res. A 2006;76(1): 144-150.
94. Klausner EA, et al. Expandable gastroretentive dosage forms. J. Control. Release 2003;90(2):143-162.
95. Shalaby WSW, Blevins WE, Park K. Gastric retention of enzyme-digestible hydrogels in the canine stomach under fasted and fed conditions: preliminary analysis using new analytical techniques. ACS Symp. Ser. 1991;469:237-248.
96. Shalaby WSW, Blevins WE, Park K. Use of ultrasound imaging and fluoroscopic imaging to study gastric retention of enzyme-digestible hydrogels. Biomaterials 1992;13(5): 289-296.
97. Groning R, et al. Compressed collagen sponges as gastroretentive dosage forms: in vitro and in vivo studies. Eur. J. Pharm. Sci. 2007;30(1):1-6.
98. Kosch O, et al. Investigation of gastrointestinal transport by magnetic marker localization. Biomed. Tech. (Berl) 2002;47 (Suppl 1 Pt 2):506-509.
99. Weitschies W, et al. Magnetic marker monitoring of esophageal, gastric and duodenal transit of non-disintegrating capsules. Pharmazie 1999;54(6):426-430.
100. Weitschies W, et al. Magnetic marker monitoring: an application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv. Drug Deliv. Rev. 2005;57(8):1210-1222.
101. Weitschies W, et al. Determination of the disintegration behavior of magnetically marked tablets. Eur. J. Pharm. Biopharm. 2001;52(2):221-226.
102. Weitschies W, et al. Magnetic marker monitoring of disintegrating capsules. Eur. J. Pharm. Sci. 2001;13(4):411-416.
103. Weitschies W, et al. Impact of the intragastric location of extended release tablets on food interactions. J. Control. Release 2005;108(2-3):375-385.
104. Andra W, et al. A novel magnetic method for examination of bowel motility. Med. Phys. 2005;32(9):2942-2944.
105. AndraW, et al. A novel method for real-time magnetic marker monitoring in the gastrointestinal tract. Phys. Med. Biol. 2000;45(10):3081-3093.
106. Agyilirah GA, et al. Evaluation of the gastric retention properties of a cross-linked polymer coated tablet versus those of a nondisintegrating tablet. Int. J. Pharm. 1991;75(2-3): 241-247.
107. Stops F, et al. The use of citric acid to prolong the in vivo gastro-retention of a floating dosage form in the fasted state. Int. J. Pharm. 2006;308(1-2):8-13.
108. Timmermans J. Comparative evaluation of the gastric transit of floating and non-floating matrix dosage forms. Bull. Mem. Acad. R. Med. Belg. 1990;145(8-9):365-375.
109. BurkeMD,et al.Anovel method to radiolabel gastric retentive formulations for gamma scintigraphy assessment. Pharm. Res. 2007;24:695-704.
110. Davies NM, et al. A comparison of the gastric retention of alginate containing tablet formulations with and without the inclusion of excipient calcium ions. Int. J. Pharm. 1994;105 (2):97-101.
111. Djaldetti R, et al. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46(4):1051-1054.
112. Hardy JG, et al. A comparison of the gastric retention of a sucralfate gel and a sucralfate suspension. Eur. J. Pharm. Biopharm. 1993;39(2):70-74.
113. Vaira D, et al. Gastric retention of sucralfate gel and suspension in upper gastrointestinal diseases. Aliment. Pharmacol. Ther. 1993;7(5):531-535.
114. Kedzierewicz F, et al. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J. Control. Release 1999;58(2):195-205.
115. Lavy E, Steinman A, Soback S. Oral controlled-release formulation in veterinary medicine. Crit. Rev. Ther. Drug Carrier Syst. 2006;23(3):165-204.
116. Illum L, Ping H. Gastroretentive controlled release microspheres for improved drug delivery. US Patent 6,207,197, 2001 (West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited, Nottingham, UK).
117. Ichikawa M, Watanabe S, Miyake Y. Granule remaining in stomach. US Patent 4,844,905, 1989 (Eisai Co., Ltd., Tokyo, Japan).
118. Dennis A, Timmins P, Lee K. Buoyant controlled release powder formulation. US Patent 5,169,638, 1992 (E. R. Squibb & Sons, Inc., Princeton, NJ).
119. Harrigan RM. Drug delivery device for preventing contact of undissolved drug with the stomach lining. US Patent 4,055,178, 1977.
120. Franz MR, OthMP. Sustained release, bilayer buoyant dosage form. US Patent 5,232,704, 1993 (G. D. Searle & Co., Chicago, IL).
121. Mitra SB. Sustained release oral medicinal delivery device. US Patent 4,451,260, 1984 (Minnesota Mining and Manufacturing Company, St. Paul, MN).
122. Shell JW. Sustained-release oral drug dosage form. US Patent 5,007,790, 1991 (DepoMed Systems, Inc., Hillsborough, CA).
123. Shell JW. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms.US Patent 5,582,837, 1996 (DepoMed, Inc., Foster City, CA).
124. Shell JW. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter. USPatent 5,972,389, 1999 (DepoMed, Inc., Foster City,CA).
125. Shell JW, Louie-Helm J, Markey M. Extending the duration of drug release within the stomach during the fed mode. US Patent 6,340,475, 2002 (DepoMed, Inc., Menlo Park, CA).
126. Shell JW, Louie-Helm J, Markey M. Extending the duration of drug release within the stomach during the fed mode. US Patent 6,635,280, 2003 (DepoMed, Inc., Menlo Park, CA).
127. Gusler G, et al. Optimal polymer mixtures for gastric retentive tablets US Patent 6,723,340, 2004 (DepoMed, Inc., Menlo Park, CA).
128. Berner B, Louie-Helm J. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms. US Patent 6,488,962, 2002 (DepoMed, Inc., Menlo Park, CA).
129. Caldwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4,767,627, 1988 (Merck&Co., Inc., Rahway, NJ).
130. Caldwell LJ, et al. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4,758,436, 1988 (Merck & Co., Inc., Rahway, NJ).
131. Pogany S, Zentner GM. Bioerodible thermoset elastomers. US Patent 5,047,464, 1991 (Merck & Co., Inc., Rahway, NJ).
132. Pogany S, Zentner GM. Bioerodible thermoset elastomers. US Patent 5,217,712, 1993 (Merck & Co., Inc., Rahway, NJ).
133. Edgren DE, Jao F, Wong PSL. Gastric retention dosage form having multiple layers. US Patent 6,797,283, 2004 (Alza Corporation, Mountain View, CA).
134. Edgren DE, et al. Method of fabricating a banded prolonged release active agent dosage form. US Patent 6,365,183, 2002 (ALZA Corporation, Mountain View, CA).
135. Wong PSL, et al. Prolonged release active agent dosage form adapted for gastric retention. US Patent 6,120,803, 2000 (ALZA Corporation, Mountain View, CA).
136. Wong PSL, et al. Prolonged release active agent dosage form adapted for gastric retention. US Patent 6,548,083, 2003 (Alza Corporation, Mountain View, CA).
137. Wong PSL, Edgren DE. Gastric retaining oral liquid dosage form. US Patent 6,635,281, 2003 (Alza Corporation, Palo Alto, CA).
138. Edgren DE, Magruder JA, Bhatti GK. Controlled release dosage form comprising different cellulose ethers. US Patent 4,871,548, 1989 (ALZA Corporation, Palo Alto, CA).
139. Curatolo WJ, Lo J. Gastric retention system for controlled drug release. US Patent, 5,002,772, 1991 (Pfizer Inc., New York, NY).
140. Curatolo WJ, Lo J. Gastric retention system for controlled drug release. US Patent, 5,443,843, 1995 (Pfizer Inc., New York, NY).
141. Flashner-Barak M, et al. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates. US Patent 6,476,006, 2002 (Teva Pharmaceutical Industries, Ltd., Petah Tiqva, Israel).
142. Flashner-Barak M, Rosenberger V, Lerner EI. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation. US Patent 6,881,420, 2005 (Teva Pharmaceutical Industries Ltd., Petah Tiqva, Israel).
143. Talwar N, Sen H, Staniforth JN. Orally administered drug delivery system providing temporal and spatial control. US Patent 6,960,356, 2005 (Ranbaxy Laboratories Limited, New Delhi, India).
144. Timmins P, Dennis AB, Vyas KA. Biphasic controlled release delivery system for high solubility pharmaceuticals and method. US Patent 6,475,521, 2002 (Bristol-Myers Squibb Co., Princeton, NJ).
145. Timmins P, Dennis AB, Vyas KA. Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method. US Patent 6,660,300, 2003 (Bristol-Myers Squibb Co., Princeton, NJ).
146. Lerner EI, Flashner M, Penhasi A. Gastrointestinal drug delivery system. US Patent 5,840,332, 1998 (Perio Products Ltd., Jerusalem, Israel).
147. Krumme M. Expandable gastroretentive therapeutical system with prolonged stomach retention time. US Patent 6,776,999, 2004 (LTS Lohmann Therapie-Systeme AG, Andernach, Germany).
148. Park K, Park H. Super absorbent hydrogel foams. US Patent, 5,750,585, 1998 (Purdue Research Foundation, West Lafayette, IN).
149. Park K, Chen J, Park H. Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties. US Patent 6,271,278, 2001 (Purdue Research Foundation, West Lafayette, IN).